MARKET

NTEC

NTEC

Intec Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.040
+0.040
+1.33%
After Hours: 3.075 +0.035 +1.15% 19:49 11/25 EST
OPEN
3.050
PREV CLOSE
3.000
HIGH
3.185
LOW
2.910
VOLUME
379.38K
TURNOVER
--
52 WEEK HIGH
15.82
52 WEEK LOW
2.200
MARKET CAP
210.57M
P/E (TTM)
-7.3876
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Intec Pharma Granted European Patent Titled 'CARBIDOPA/LEVODOPA GASTRORETENTIVE DRUG DELIVERY'
https://data.epo.org/publication-server/pdf-document?pn=3115043&ki=B1&cc=EP
Benzinga · 1d ago
Intec Pharma EPS misses by $0.15
Intec Pharma (NTEC): Q3 GAAP EPS of -$0.95 misses by $0.15.Cash and cash equivalents of $17.1M.Press Release
Seekingalpha · 11/05 12:28
Intec Pharma Q3 EPS $(0.95) Down From $(0.61) YoY
Intec Pharma (NASDAQ:NTEC) reported quarterly losses of $(0.95) per share. This is a 55.74 percent decrease over losses of $(0.61) per share from the same period last year.
Benzinga · 11/05 12:11
TWTR, CVA, OPK and BLRX among midday movers
 Gainers: BioLineRx (BLRX) +76%.Marine Petroleum Trust (MARPS) +65%.DASAN Zhone Solutions (DZSI) +25%.Air Industries (AIRI) +21%.Rogers (ROG) +20%.Acadia Healthcare (ACHC) +18%.Tricida (TCDA) +17%.Covanta Holding (CVA) +16%.MoneyGram International (MGI) +14%.Daseke (DSKE) +14%.Losers: Axovant Gene
Seekingalpha · 10/30 16:41
Intec Pharma Announces 1-for-20 Reverse Share Split, Will Begin Trading On Split-Adjusted Basis On Oct. 30
JERUSALEM, Oct. 29, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today announces a 1-for-20 reverse share split of its outstanding ordinary shares. The reverse share
Benzinga · 10/29 12:30
Intec Pharma Announces 1-for-20 Reverse Share Split
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces a 1-for-20 reverse share split of its outstanding ordinary shares. The reverse share split is scheduled to become effective after trading closes on October 29, 2020, and the Company's ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market at the commencement of trading on October 30, 2020 under the Company's existing symbol "NTEC." The Company's ordinary shares have been assigned a new CUSIP number of M53644148 in connection with the reverse share split. As previously disclosed, at the Company's Annual Meeting of Shareholders held on July 15, 2020, the Company's shareholders approved a proposal to amend the Company's Articles of Association to effect a reverse share split of the Company's ordinary shares at a ratio with the range from 1-for-5 to 1-for-25, to be effective at the ratio and on a date to be determined by the Company's board of directors in its sole discretion.
PR Newswire · 10/29 12:00
Intec Pharma/MSD ink research deal; shares up 13%
Intec Pharma (NTEC) +13% premarket after announcing a new research collaboration agreement with MSD, the tradename of Merck & Co, USA.The details of the agreement are not disclosed."This new agreement builds upon
Seekingalpha · 10/08 11:39
Intec Pharma Announces New Research Collaboration Agreement with MSD
JERUSALEM, Oct. 8, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the tradename of
Benzinga · 10/08 11:02
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NTEC. Analyze the recent business situations of Intec Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NTEC stock price target is 7.50 with a high estimate of 10.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 71
Institutional Holdings: 9.95M
% Owned: 14.37%
Shares Outstanding: 69.27M
TypeInstitutionsShares
Increased
4
6.60K
New
12
-74.29K
Decreased
5
69.85K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Director
John Kozarich
Chief Executive Officer/Vice Chairman/Director
Jeffrey Meckler
Chief Financial Officer
Nir Sassi
Chief Operating Officer
Nadav Navon
Chief Administrative Officer
Walt Linscott
Vice President
Liat Flaishon
Other
R. Michael Gendreau
Director
William Hayes
Director
Roger Pomerantz
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NTEC
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Intec Pharma Ltd stock information, including NASDAQ:NTEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTEC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NTEC stock methods without spending real money on the virtual paper trading platform.